Santhera Pharmaceuticals provided a corporate update following implementation of an organizational restructuring and its move to a focus on vamorolone, a dissociative steroid with a novel mode of action, to which the Company recently obtained global rights in all indications. At the Executive Management level, Santhera will see a change with the departure of Kristina Sjöblom Nygren, Chief Medical Officer and Head of Development, for family reasons and to pursue other opportunities. The search for a successor to secure a seamless transition has been initiated.